AIDS across Europe, 1994-98: The EuroSIDA study

Lancet

Volumn 356, Issue 9226, 2000, Pages 291-296

  Mocroft, A ^a   Katlama, C ^b   Johnson, A M ^a   Pradier, C ^c   Antunes, F ^d   Mulcahy, F ^e   Chiesi, A ^f   Phillips, A N ^a   Kirk, O ^g   Lundgren, J D ^g  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e ST JAMES S HOSPITAL   (Ireland)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL FEATURE; EUROPE; HUMAN; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETINITIS;

EID: 0003248215     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02504-6     Document Type: Article

References (35)

1. Mocroft A.J., Johnson M.A., Sabin C.A.et al. Staging system for clinical AIDS patients. Lancet. 346:1995;12-17.
2. Hanson D.L., Horsburgh C.R., Fann S.A., Havlik J.A., Thompson S.E. Survival prognosis of HIV-1 infected patients. J Acquir Immune Defic Syndrome Hum Retrovirol. 6:1993;624-629.
3. Turner B.J., Markson L.E., McKee L., Houchers R., Fanning T. The AIDS-defining diagnosis and subsequent complications. a survival based severity index J Acquir Immun Defic Syndr Hum Retrovirol. 4:1991;1059-1071.
4. 3. J Infect Dis. 170:1994;1284-1287.
5. Moore R.D., Chaisson R.E. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 124:1996;633-642.
6. Mocroft A., Youle M., Phillips A.N.et al. The incidence of AIDS defining illnesses in 4883 patients with human immunodeficiency virus infection. Arch Intern Med. 158:1998;491-497.
7. Hanson D.L., Chu S.Y., Farizio K.M., Ward J.W. Distribution of CD4+ lymphocytes at diagnosis of Acquired Immunodeficiency Syndrome - Defining and other human immunodeficiency virus related illnesses. Arch Intern Med. 155:1995;1537-1542.
8. Phillips A.N., Lee C.A., Elford J.et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet. 337:1991;389-392.
9. Crowe S.M., Carlin J.B., Stewart K.I., Lucas C.R., Hoy J.F. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr Hum Retrovirol. 4:1991;770-776.
10. Brodt H.R., Kamps B.S., Gute P., Knupp B., Staszewski S., Helm E.B. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 11:1997;1731-1738.
11. Spira R., Marimoutou C., Binquet C., Lacoste D., Dabis F. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France 1995-1997. J Acquir Immune Defic Syndr Hum Retrovirol. 18:1998;358-364.
12. Paella F.J., Delaney K.M., Moorman A.C.et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 338:1998;853-860.
13. Mouton Y., Alfandari S., Valette M.et al. mpact of protease inhibitors on AIDS defining events and hospitalisations in 10 French AIDS reference centres. AIDS. 11:1997;F101-F105.
14. Jacobson M.A., Zegans M., Pavan P.R.et al. Cytomegalovirus after initation of highly active antiretroviral therapy. Lancet. 349:1997;1443.
15. Mitchelet C., Arvieux C., Francois C.et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 12:1998;1815-1822.
16. Anonymous. 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus: USPHS-IDSA Prevention of Opportunistic Infections Working Group. MWWR 1999; 48 (RR10): 1-59.
17. Law M.G., de Winter L., McDonals A., Cooper D.A., Kaldor K.N. AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral therapy. AIDS. 13:1999;263-269.
18. Egger M. Opportunistic Infections in the era of HAART: 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Abstract 76.
19. Pezzotti P., dal Maso L., Serraino D., Franchesci S., Rezza G. Has the spectrum of AIDS-deining illnesses been changing since the introduction of new treatments and combinations of treatments. J Acquir Immune Defic Syndr Hum Retrovirol. 20:1999;515-516.
20. Jones J., Hanson D., Dworkin M., Kaplan J. Which opportunistuc illnesses occur in the era of HAART and at ehat CD4 cell counts? 6th Conference on Retrovirus and Opportunistic Infections. 1999;. Abstract 690.
21. Forrest D.M., Seminari E., Hogg R.S.et al. The incidence and spectrum of AIDS-defining illnesses in person treated with antiretroviral drugs. Clin Infect Dis. 27:1998;1379-1385.
22. Lundgren J.D., Phillips A.N., Vella S.et al. Regional differences in the use of antiretrovirals and primary prophylaxis in 3122 European HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 16:1997;153-160.
23. Phillips A.N., Katlama C., Barton S.et al. Survival in 2367 zidovudine treated patients according to use of other nucleoside analogue drugs. J Acquir Immune Defic Syndr Hum Retrovirol. 17:1998;239-244.
24. 1993 revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults. MMWR. 41(RR-17):1992;1-19.
25. Kirk O., Mocroft A., Katzenstein T.L.et al. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS. 12:1998;2031-2039.
26. Miller V., Straszewski S., Nisius G., Cozzi Lepri A., Sabin C., Phillips A.N. Risk of new AIDS diseases in people on triple therapy. Lancet. 353:1999;462.
27. Cameron D.W., Heath-Chiozzo M., Danner S.et al. Randomised placebo controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 351:1998;543-549.
28. Hammer S.M., Squires K.E., Hughes M.D.et al. A controlled trials of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med. 337:1997;725-733.
29. Montaner J.S.G., Reiss P., Cooper D.et al. A randomised, double blind trial comparing combinations of nevaripine, didanosine, and zidovudine for HIV-infected patients. the INCAS trial JAMA. 279:1998;930-937.
30. Weverling G.J., Mocroft A., Ledergerber B.et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet. 353:1999;1293-1298.
31. MacMahon E.M.E., Glass J.D., Hayward S.D.et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 338:1991;969-993.
32. Gaidano G., Carbone A., Dalla-Favera R. Pathogenesis of AIDS-related lymphomas. molecular and histogenetic heterogeneity Am J Pathol. 152:1998;623-630.
33. Mocroft A., Sabin C.A., Youle M.et al. Changes in AIDS defining illnesses, Royal Free Hospital 1987-1998. J Acquir Immune Defic Syndr Hum Retrovirol. 21:1999;401-407.
34. Ledergerber B., Telenti A., Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkins lymphoma with potent antiretroviral therapy.: prospective cohort study. BMJ. 319:1999;23-24.
35. Jones J.L., Hanson D.L., Dworkin M.S., Ward J.W., Jaffe H.W. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immune Defic Syndr Hum Retrovirol. 21:1999;S11-S17.